pegylated interferon alpha-2b
ApprovedSmall molecule
Merck & Co.pegylated interferon alpha-2b is one of 95 small molecule programs targeting Pilocytic Astrocytoma. It is currently in Approved.
4
Indications
10
Total Trials
0
Active Trials
94
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Libtayo
RegeneronPhase 3
Imjudo
AstraZenecaPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Incomplete Freund's Adjuvant
EEastern Cooperative Oncology Group
Phase 3
pegylated interferon alpha-2b
Merck & Co.Approved
Epacadostat
IncytePhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis3 trials
Melanoma3 trials
Treatment1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company